Key Facts

Invested since 2023
Based in Bavaria

About the company

Hema To Team

hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as well as patients. hema.to is a CE-IVD, FDA registered and already in routine use by leading hematology laboratories. Founded in 2021, hema.to’s mission is to make clinical analysis of cytometry data completely objective, to enable doctors to personalize treatment to their patient’s unique immune system.

Do you want to

know more about this company?

Zum Artikel

Dr. Nikolaus Raupp Principal

Dr. Nikolaus RauppPrincipal

hema.to in the news

Zum Artikel

News

27. February 2025

German digital medtech startup hema.to receives €3.6 million investment from LUMO Labs and Bayern Kapital for AI-based blood data analysis.

Hema To Team Zum Artikel

News

26. June 2023

hema.to raises €3.6M to bring precision diagnostics to immune medicine using AI-assisted analysis of single-cell blood data

More startups from Life Sciences